A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma-Reference-Cited by-同舟云学术

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

Published:2005-07-29 Issue:4 Volume:57 Page:533-539
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Jermann Monika,Stahel Rolf A,Salzberg Marc,Cerny Thomas,Joerger Markus,Gillessen Silke,Morant Rudolf,Egli Fritz,Rhyner Kaspar,Bauer Jean A,Pless Miklos

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-005-0070-z.pdf

Reference29 articles.

1. Asakuma J, Sumitomo M, Asano T et al (2004) Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. J Urol 171:897–902

2. Atzpodien J, Kirchner H, Illiger HJ et al (2001) IL-2 in Combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85:1130–1136

3. Atzpodien J, Kirchner H, Jonas U et al (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194

4. Dawson NA, Guo C, Zak R et al (2004) A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10:7812–7819

5. Drucker B, Bacik J, Ginsberg M et al (2003) Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drug 21:341–345

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression and Prognostic Significance of Ferroptosis-related Proteins SLC7A11 and GPX4 in Renal Cell Carcinoma;Protein & Peptide Letters;2023-10

2. A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma;Clinical Genitourinary Cancer;2022-10

3. Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma;Journal of Experimental & Clinical Cancer Research;2021-08-16

4. Claspin overexpression is associated with high‐grade histology and poor prognosis in renal cell carcinoma;Cancer Science;2020-02-03

5. Cystic Kidney Diseases Associated with Increased Cancer Risk: Tuberous Sclerosis Complex, Von Hippel-Lindau, and Birt-Hogg-Dubé;Polycystic Kidney Disease;2018